Header

UZH-Logo

Maintenance Infos

Effects of the progestagen-only contraceptive implant Implanon on transforming growth factor beta1 and endothelin-1


Merki-Feld, G S; Imthurn, B; Seifert, Burkhardt (2008). Effects of the progestagen-only contraceptive implant Implanon on transforming growth factor beta1 and endothelin-1. Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et métabolisme, 40(10):692-696.

Abstract

Progestagen-only contraceptives are often prescribed to women with an increased cardiovascular risk, despite the fact that only few data are available on the effect of these contraceptives on circulating biomarkers of inflammation and endothelial function. In our prospective case-control study, we aimed to investigate the influence of the low-dose etonogestrel-releasing contraceptive implant Implanon® on endothelin-1 and cytokine transforming growth factor β (TGF-β1), both factors involved in the early phases of atherogenesis. We also were interested in searching for an interrelation between changes in these two parameters and changes in female hormones and plasma lipids. Cases (n=20) were women using Implanon® for contraception, and controls (n=20) were females not using hormonal contraception. Baseline blood samples were taken during the early follicular phase of cycle 1 in both groups. A second sample was taken 12 weeks after Implanon® insertion or, for controls, in the early follicular phase of cycle 4. In both groups no significant change in endothelin-1 or TGF-β1 was observed. In Implanon® users, cholesterol, high-density lipoprotein, low-density lipoprotein, sex hormone-binding globulin, and testosterone decreased significantly. No correlations were found between endothelin-1 or TGF-β1 and the investigated parameters. The results suggest that Implanon® does not exert a clinically relevant negative effect on endothelin-1 or TGF-β.

Abstract

Progestagen-only contraceptives are often prescribed to women with an increased cardiovascular risk, despite the fact that only few data are available on the effect of these contraceptives on circulating biomarkers of inflammation and endothelial function. In our prospective case-control study, we aimed to investigate the influence of the low-dose etonogestrel-releasing contraceptive implant Implanon® on endothelin-1 and cytokine transforming growth factor β (TGF-β1), both factors involved in the early phases of atherogenesis. We also were interested in searching for an interrelation between changes in these two parameters and changes in female hormones and plasma lipids. Cases (n=20) were women using Implanon® for contraception, and controls (n=20) were females not using hormonal contraception. Baseline blood samples were taken during the early follicular phase of cycle 1 in both groups. A second sample was taken 12 weeks after Implanon® insertion or, for controls, in the early follicular phase of cycle 4. In both groups no significant change in endothelin-1 or TGF-β1 was observed. In Implanon® users, cholesterol, high-density lipoprotein, low-density lipoprotein, sex hormone-binding globulin, and testosterone decreased significantly. No correlations were found between endothelin-1 or TGF-β1 and the investigated parameters. The results suggest that Implanon® does not exert a clinically relevant negative effect on endothelin-1 or TGF-β.

Statistics

Citations

4 citations in Web of Science®
4 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 03 Dec 2008
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
04 Faculty of Medicine > University Hospital Zurich > Clinic for Reproductive Endocrinology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:October 2008
Deposited On:03 Dec 2008 08:22
Last Modified:06 Dec 2017 14:36
Publisher:Thieme
ISSN:0018-5043
Publisher DOI:https://doi.org/10.1055/s-2008-1073149
PubMed ID:18500679

Download